Published Papers in Referred Journals

Latest publications in PubMed

  1. Sadat SMA, Saeidnia S, Nazarali A and Haddadi A; “Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer”, Current Cancer Drug Target, 2015;15(1):71-86.
  2. Rafiei P, Mitchel D and Haddadi A; “Application of a Rapid ESI-MS/MS method for quantitative analysis of docetaxel in polymeric matrices of PLGA and PLGA-PEG nanoparticles through direct injection to mass spectrometer”; American Journal of Analytical Chemistry, 2015; 6(2):164-175.
  3. Izadifar M, Haddadi A, Kelly ME and Chen XB; “Rate-programming of nano-particulate delivery systems for smart bioactive scaffolds in tissue engineering”, Nanotechnology, 2015; 26(1):012001.
  4. Haddadi A, Hamdy S, Ghotbi Z, Samuel J and Lavasanifar A; “Immunoadjuvant Activity of Nanoparticles Surface Modified with Mannan”, Nanotechnology, 2014; 25(35):355101.
  5. Saeidnia S, Gohari AR, Haddadi A, Amin G., Nikan M and Hadjiakhoondi A; “Presence of Monoterpene Synthase in four Labiatae Species and Solid-Phase Microextraction-Gas Chromatography-Mass Spectroscopy Analysis of their Aroma Profiles”, Pharmacognosy Research. 2014; 6(2): 138-142.
  6. Saeidnia S, Gohari AR and Haddadi A, “Biogenic trypanocidal sesquiterpenes: lead compounds to design future trypanocidal drugs - a mini review”, Daru Journal of Pharmaceutical Sciences. 2013 15;21(1): 35.
  7. Korbelik M, Madyalakan R, Woo T and Haddadi A, “Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052”, Photochemistry and photobiology, 2012, 88 (1): 188-93.
  8. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, and Lavasanifar A; “Activation of antigen specific T cell responses by mannan-decorated PLGA nanoparticles”, Pharmaceutical Research, 2011 Sep; 28(9): 2288-301.
  9. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, and Lavasanifar A; “Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles”, J Drug Targeting, 2011, 19(4): 281-292.
  10. Hamdy S, Haddadi A, Hung RW and Lavasanifar A. “Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations” Advanced Drug delivery Reviews, 2011; 63(10-11): 943-55.
  11. Hamdy S, Haddadi A, Ghotbi Z, Hung RW, and Lavasanifar A; “Part I: Targeted particles for cancer immunotherapy”, Current Drug Delivery, 2011, 8 (3): 261-273.
  12. Alshamsan A, Hamdy S, Haddadi A, Samuel J, Uludag H, El-Kadi A, and Lavasanifar A., STAT3 knockdown in B16 melanoma by si-RNA Lipopolyplexes induces bystander immune response in vitro and in vivo. Translational oncology. 2011, 4: 178-188.
  13. Hamdy S, Haddadi A, Shayeganpour A., Alshamsan A., Montazeri Aliabadi HR. and Lavasanifar A.; “The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies”, The AAPS Journal, 2011, 13 (2): 159-168.
  14. Hung RW., Hamdy S., Haddadi A., Ghotbi Z. and Lavasanifar A.; “Part II: Targeted particles for imaging of anticancer immune responses”, Current Drug Delivery, 2011, 8 (3): 274-281.
  15. Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi, AUludag H, and Lavasanifar A., “STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response”. Molecular Pharmaceutics, 2010, 7 (5), pp 1643–1654
  16. Alshamsan A, Haddadi A, Incani V, Samuel J, El-Kadi A, Lavasanifar A and Uludag H; “Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine”, Molecular Pharmaceutics, 2009, 6 (1): 121–133.
  17. Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J and Samuel J, “Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells”. Journal of Biomedical Material Research, 2008, 84A (4): 885-898.
  18. Haddadi A, Farboud ES, Erfan M, Aboofazeli R; “Preparation and characterization of w/o and o/w creams containing urea loaded PLGA microspheres”. Journal of Microencapsulation, 2008, 25(6): 379-386.
  19. Das S., Haddadi A, Veniamin S. and Samuel J.; “Delivery of rapamycin-loaded nanopaerticles down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34+ progenitor-derived dendritic cells”. Journal of Biomedical Material Research, 2008, 85A(4): 983-992.
  20. Ma Z., Haddadi A., Molavi O., Lavasanifar A., Lai R and Samuel J., “Micelles of poly(ethylene oxide)-b-poly(e-caprolactone) as vehicles for the solubilization, stabilization and controlled delivery of curcumin”. Journal of Biomedical Material Research, 2008, 86 (2): 300-10.
  21. Ma Z, Molavi O, Haddadi A, Lai R, Gossage R and Lavasanifar A; “Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol”. Cancer Chemother Pharmacol. 2008,63 (1): 27-35.
  22. Hamdy S., Molavi O, Ma Z, Haddadi A, Alshamsan A, Ghotbi Z, Elhasi S, Samuel J and Lavasanifar A.; “Co-delivery of cancer associated antigen and Toll like receptor 4 ligand PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity”, Vaccine 2008, 26(39): 5046-5057.
  23. Hamdy S, Haddadi A, Somayaji V, Ruan D and Samuel J, “The pharmaceutical analysis of synthetic lipid A-based vaccine adjutants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations”. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44(4): 914-923.
  24. Haddadi A, Farboud ES, Erfan M, Aboofazeli R; “Preparation and characterization of biodegradable urea loaded microparticles as an approach for transdermal delivery” Journal of Microencapsulation, 2006, 23 (6): 698-712.

Invited Lectures & Conference Presentations

  1. “Polymeric Nanoparticles for Cancer Therapy”, 7th Annual World Cancer Congress (WCC-2014), Nanjing, China, May 2014
  2. “Fighting Cancer with Nanomedicine: Immunotherapy and Photodynamic Therapy”, Avicenna (Bu-Ali) Research Institute, Mashhad, Iran, May 2014
  3. “PLGA Nanoparticles for Immunomodulation”, Western Canadian Medicinal Chemistry Workshop (WCMCW), University of Saskatchewan, September 2010.
  4. “Multifactor Attack Against Cancer”, Faculty of Pharmacy, U of Manitoba, February 2010

Conferences

  1. Jahan ST, P Rafiei, Sadat SMA and Haddadi A, “Polymeric Nanoparticles for Cancer Therapy”, 7th Annual World Cancer Congress, Nanjing, China, May 2014
  2. Sams SMA and Haddadi A, “Trastuzumab Modified Targeted Nanoparticles for HER2 Positive Breast Cancer”, 2014 CSPS/CC-CRS Joint Conference, Montreal, June 2014
  3. Jahan ST and Haddadi A, “Targeting CD205 receptor as an Approach to Develop a Cancer Vaccine”, 2014 CSPS/CC-CRS Joint Conference, Montreal, June 2014
  4. Rafiei P and Haddadi A, “Docetaxel-loaded polymeric nanoparticles of PLGA for sustained release intravenous application: preparation and in vitro characterization”, 2014 CSPS/CC-CRS Joint Conference, Montreal, June 2014
  5. Jahan ST and Haddadi A, “Evaluation of dendritic cell uptake and expression of maturation markers: Two important factors for targeted nanoparticle vaccine delivery system”, 5th Annual Canadian Pharmacy Education and Research Conferecne (CPERC) and Association of Faculties of Pharmacy of Canada (AFPC) Annual Conference 2014, May 31 - June 3, 2014, Saskatoon,Canada
  6. Sams SMA and Haddadi A, “Targeted Chemotherapy: An Innovative Approach against HER2 Positive Breast Cancer”, 5th Annual Canadian Pharmacy Education and Research Conferecne (CPERC) and Association of Faculties of Pharmacy of Canada (AFPC) Annual Conference 2014, May 31 - June 3, 2014, Saskatoon, Canada
  7. Rafiei P, Mitchel D and Haddadi A, “Preparation of PLGA and PLGA-PEG nanoparticles and determination of docetaxel loading characteristics through a rapid ESI-MS/MS method”, 5th Annual Canadian Pharmacy Education and Research Conferecne (CPERC) and Association of Faculties of Pharmacy of Canada (AFPC) Annual Conference 2014, May 31 - June 3, 2014, Saskatoon, Canada
  8. Jahan ST and Haddadi A, “Development of targeted PLGA nanoparticle vaccine delivery system for cancer immunotherapy”, 21st Annual Health Sciences Research Day, March 2014
  9. Sams SMA and Haddadi A, “Tailor-made PLGA nanoparticles for targeted drug delivery to HER2 positive breast cancer”, 21st Annual Health Sciences Research Day, March 2014
  10. Madiyalakan M and Haddadi A, “Immunotherapy in Combination with Photodynamic therapy: A Preclinical study with human MUC1 transgenic mouse model”, The 14th World Congress of the International Photodynamic Association (IPA), May 2013, Republic of Korea
  11. ST Jahan and A Haddadi, “Decoration of nanoparticles to target dendritic cells as an approach for cancer immunotherapy”, 12th Saskatchewan Cancer Research Day, Saskatoon, Dec 2012
  12. P Rafiei and A Haddadi, “Preparation and characterization of docetaxel loaded PLGA nanoparticles for cancer chemotherapy”, Cancer Research Day, University of Saskatchewan, Dec 2012.
  13. M Wallisser, ST Jahan and A Haddadi, “Evaluating the cytotoxicity of PLGA-based nanoparticle drug delivery systems”, Modern Therapeutics Conference, June 2012, Toronto.
  14. A Haddadi and Z Ma, “Nanoparticle Delivery of Cancer Antigens to Modulate Anticancer Immune Responses in-vivo”, 11th Saskatchewan Cancer Research Day, Saskatoon, Dec 2011
  15. ST Jahan, M Wallisser and A Haddadi, “Developing Targeted Nanoparticles for Cancer Immunotherapy”, 11th Saskatchewan Cancer Research Day, Saskatoon, Dec 2011
  16. A. Haddadi, 2010.   PLGA Nanoparticles for Immunomodulation, WCMCW, University of Saskatchewan, September.
  17. A Alshamsan, S Hamdy, A Haddadi, J Samuel, A El-Kadi, H Uludag, A Lavasanifar, 2010. Down-Modulation of Stat3 in B16 Melanoma by Lipid- modified PEI/siRNA Nano-complexes: Implications in Cancer Immunotherapy, 37th Annual Meeting & Exposition of the Controlled Release Society. Oregon, USA
  18. A. Haddadi, S. Hamdy, Z. Ghotbi, J. Samuel and A. Lavasanifar, 2009.  Mannose Receptor Targeting Potentiates Immunostimulatory Effect of Vaccine Delivery Systems, AAPS Annual Meeting and Exposition, Los Angeles CA.
  19. A. Alshamsan, A. Haddadi, S. Hamdy, J. Samuel, H. Uludag, A. El-Kadi and A. Lavasanifar, 2009.  Targeting Dendritic Cells with PLGA Nanoparticles of Anti-STAT3 siRNA Breaks Cancer-Mediated Immune Tolerance, AAPS Annual Meeting and Exposition, Los Angeles CA.
  20. Z. Ghotbi, A. Haddadi, S. Hamdy, R.W. Hung, J. Samuel and A. Lavasanifar, 2009.  Dendritic Cell (DC) Targeting with Mannan-adsorbed Poly (D, L-lactide-co-glycolide) (PLGA) Nanospheres, AAPS Annual Meeting and Exposition, Los Angeles CA.
  21. S. Hamdy, A. Alshamsan, A. Shayeganpour, A. Haddadi, H. Montazeri Aliabadi and A. Lavasanifar A, 2009.  The Immunosuppressive Activity of Polymeric Micellar Formulation of Cyclosporin A: In Vitro and In Vivo Studies, AAPS Annual Meeting and Exposition, Los Angeles CA.
  22. A. Haddadi, Z. Ma, S. Hamdy, J. Samuel and A. Lavasanifar A, 2008.  Co-delivery of a New Generation of MUC1 Antigens and Toll-like Receptor Ligands by Biodegradable Nanoparticles elicit Strong T cell Responses, CSPS 11th Annual Symposium, Banff AB, May.
  23. A. Alshamsan, A. Haddadi, V. Incani, J. Samuel, A. Lavasanifar and H. Uludağ H, 2008.  Oleic-Acid and Stearic-Acid Modification of Polyethylenimine Improved siRNA Silencing Effect in B16 Melanoma, CSPS 11th Annual Symposium, Banff AB, May.
  24. Z. Ghotbi, A. Haddadi, S. Hamdy, A. Mahmud, J. Samuel and A. Lavasanifar, 2008.  Development of Surface-anchored PLGA Nanospheres with Mannose-receptor Ligands for Targeting Dendritic Cells in Cancer Immunotherapy, CSPS 11th Annual Symposium, Banff AB, May.
  25. Z. Ma, O. Molavi, A. Haddadi, R. Lai, R.A. Gossage and A, Lavasanifar, 2008.  Resveratrol Analog Trans 3,4,5,4'-tetramethoxystilbene (DMU-212) Modulates Multiple Cellular Targets in Breast Cancer Cells, CSPS 11th Annual Symposium, Banff AB, May.
  26. S. Hamdy, O. Leila, Z. Ma, A. Haddadi, Z. Gobti, S. El Hasi, A. Alshamsan, J. Samuel and A. Lavasanifar, 2008.  Therapy of Established B16 Melanoma Tumors by Vaccination with Melanoma Antigen Co-encapsulated with Adjuvant in PLGA Nanoparticles, CSPS 11th Annual Symposium, Banff AB, May.
  27. H. Uludag, A. Alshamsan, A. Haddadi, V. Incani, J. Samuel and A. Lavasanifar, 2008.  Delivery of siRNA by Lipid-modified Poly(ethyleneimine): Lipid Substitution improves siRNA Stability in Serum, 8th World Biomaterials Congress, Amsterdam, Netherlands.
  28. A. Haddadi, Z. Ma, Z. Ghotbi and J. Samuel, 2007.  Modulating of Anticancer Immune Responses by Co-delivery of MUC1 Antigen and a Toll-like Receptor Ligand PET Lipid A (Synthetic Mimic of Lipid A) in PLGA Nanoparticles, CSPS 10th Annual Symposium, Montreal QC, May.
  29. A. Alshamsan, A. Haddadi, V. Incani, H. Uludağ and J. Samuel, 2007.  Formulation of  siRNA Nanoplexes using Novel Derivatives of PEI, CSPS, 10th Annual Symposium/18th Pharmaceutical & Biomedical Analysis (PBA) Annual Meeting/64th Association of Faculties of Pharmacy of Canada (AFPC) Annual Meeting, Montréal QC, May.
  30. S. Hamdy, A. Haddadi, A. Alshamsan, V. Somayaji, D. Ruan, D. Yalamati, R. Koganti and J. Samuel, 2007.  Pharmaceutical Analysis of Synthetic Lipid A-based Caccine Adjuvants in Poly (D,L-lactic-co-glycolic acid) Nanoparticle Formulations, CSPS 10th Annual Symposium, Montreal QC, May.
  31. Z. Ghotbi, A. Haddadi, S. Hamdy, L. Wiebe and J. Samuel, 2007.  Development of a Micro-Positron Emission Tomography (PET) Probe Loaded in Poly (D, Llactide- co-glycolide) (PLGA) Nanoparticles for Dendritic Cells Tracking, CSPS 10th Annual Symposium, Montreal QC, May.
  32. S. Hamdy, P. Elamanchili, A. Haddadi and J. Samuel, 2007.  Enhanced Antigen-specific Primary CD4+ T Cell Responses by Co-delivery of Ovalbumin and Monophosphoryl Lipid A in Poly(D,L-lactic-co-glycolic acid) Nanoparticles, Anti-Tumor Immunotherapies, Keystone Symposia, March.
  33. A. Haddadi, P. Elamanchili, A. Lavasanifar and J. Samuel, 2006.  Rapamycin Encapsulated in PLGA Nanoparticles for Delivery to Dendritic Cells:  Phenotypic and Functional Aspects, Controlled Release Society Annual Meeting, Vienna, Austria, July 22-26.
  34. A. Haddadi, E.S. Farboud, M. Erfan and R. Aboofazeli, 2005.  Moisturizing Agents Encapsulated in PLGAp for Site Specific Delivery, AAPS Annual Meeting and Exposition, Prato, Italy, September.
  35. A. Haddadi, P. Elamanchili, A. Lavasanifar and J. Samuel, 2004.  Rapamycin in PLGA Nanoparticles Efficiently inhibits Maturation of Dendritic Cells as compared to Rapamycin in Solution Canada-Japan Nano and Smart Delivery Systems Symposium, Banff AB, August.
  36. A. Haddadi, R. Aboofazeli, E.S. Farboud and M. Erfan, 2004.  Comparison of the Microsphere Characteristics between PLGA, Ethyl Cellulose or Cellulose Acetate Phthalate Polymers, Canada-Japan Nano and Smart Delivery Systems Symposium, Banff AB, August.
  37. A. Haddadi, R. Aboofazeli, E.S. Farboud and M. Erfan, 2004.  An Encapsulation Technique for Highly Water Soluble Drugs:  Drug Loading and Release Studies, CSPS 7th Annual Symposium, Vancouver BC, June.
  38. A. Haddadi, P. Elamanchili, A. Lavasanifar and J. Samuel, 2004.  Rapamycin-loaded Nanoparticles Prepared by Solvent Evaporation Method: Drug Loading and Release Studies, CSPS 7th Annual Symposium, Vancouver BC, June.
  39. A. Haddadi, A. Lavasanifar and J. Samuel, 2003.  Preparation of Rapamycin-loaded Nanoparticles: Analysis of Rapamycin by High- Performance Liquid Chromatography with Ultraviolet, Nanoscience and Nanotechnology Symposium, Edmonton AB, November.
  40. A. Haddadi, R. Aboofazeli and E.S. Farboud, 2003.  Evaluation of Various Parameters involved in Preparation of PLGA Nanoparticles and Microparticles, Nanoscience and Nanotechnology Symposium, Edmonton AB, November.
  41. A. Haddadi and M. Mahmoudian, 2001.  3-Dimensional Modeling of Opioid Receptor like Receptor, International Pharmaceutical Federation (FIP) Congress Singapoor, September.
  42. A. Haddadi and N. Forutan, 2001.  Modeling of Somatostatin Receptors: SSTR1 and SSTR4, 7th Pharmacy Seminar, Kerman, Iran, April.A. Haddadi and M. Mahmoudian, 2000.  ORL1, Computer-aided Molecular Modeling, 7th Iranian Seminar of Pharmaceutical Scientists (ISPS), Mashad, Iran, August.
  43. A. Haddadi and A. Kazerooni, 2000.  Molecular Modeling of Serotonin Receptors:  5HT4 and 5HT7, 6th Pharmacy Seminar, Isfahan, Iran. March.
  44. A. Haddadi and M. Mahmoudian, 1995.  Docking of Naloxon in Dopioid Receptor, 1st Pharmacy Seminar, Tehran, Iran, March.
  45. A. Haddadi and M. Mahmoudian, 1995.  Computer-aided Molecular Modeling of m, k and d Opioid Receptors, 12th International Congress of Physiology and Pharmacology, Tehran, Iran, November.